Page 125 - Drug Class Review

Drug Effectiveness Review Project
Groups similar at baseline: No (gender distribution differed significantly)
Alzheimer classification: Mild-moderate

donepezil galantamine 73.8 75.1 51.6 71.4 NR NR 73.5 74.6 3.1 3.2 Primary Outcome Measures: Physician’s and Caregiver’s Satisfaction Questionnaires (developed by Secondary Outcome Measures: ADAS-Cog 11; ADAS-Cog 13; MMSE; DAD (40-item) Timing of assessments: Weeks 4, 8 and 12; cognitive assessments at screening, weeks 4, 8 and 12 Health Outcome Measures: DON-treated patients had significantly better physician and caregiver satisfaction scores at endpoint (P < 0.01). Significantly greater improvement of DAD scores for DON than GAL- treated pati

Pfizer and Eisai) • • Interm • • •

Final Report Update 1 Authors: Jones et al. Year: 2004 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: Other germane population qualities: Mean age onset AD diagnosis • Months since diagnosis • (median) OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs